Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Operating Leases (2019 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Operating Leases for 7 consecutive years, with $24.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 20.0% to $24.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.0 million, a 20.0% decrease, with the full-year FY2025 number at $24.0 million, down 20.0% from a year prior.
  • Operating Leases was $24.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $21.7 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $36.8 million in Q1 2021 to a low of $14.8 million in Q2 2023.
  • A 5-year average of $26.8 million and a median of $26.8 million in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: crashed 42.69% in 2023, then skyrocketed 73.4% in 2024.
  • Ultragenyx Pharmaceutical's Operating Leases stood at $30.9 million in 2021, then crashed by 35.89% to $19.8 million in 2022, then skyrocketed by 54.31% to $30.6 million in 2023, then decreased by 1.88% to $30.0 million in 2024, then fell by 20.0% to $24.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Operating Leases are $24.0 million (Q4 2025), $21.7 million (Q3 2025), and $24.5 million (Q2 2025).